Small Cell Lung Cancer Trials

Clinical Trial of Lurbinectedin as Single-agent or in Combination With Irinotecan Versus Topotecan or Irinotecan in Patients With Relapsed Small-cell Lung Cancer (LAGOON) Identifier:             NCT05153239     
This study is currently recruiting participants.
Multicenter, open-label, randomized, controlled phase III clinical trial to evaluate and compare the activity and safety of two experimental arms consisting of lurbinectedin as single agent (Group A) or the combination of lurbinectedin with irinotecan (Group B) versus Investigator's Choice (topotecan or irinotecan) as control arm (Group C), in Small-cell Lung Cancer (SCLC) patients who failed one prior platinum-containing line.

McGill University Health Centre (MUHC), Montreal
University Health Network - Princess Margaret Hospital, Toronto

SWOG S1827 (MAVERICK) Testing Whether the Use of Brain Scans Alone Instead of Brain Scans Plus Preventive Brain Radiation Affects Lifespan in Patients With Small Cell Lung Cancer Identifier:             NCT04155034     
This study is currently recruiting participants.
This phase III trial studies magnetic resonance imaging (MRI) surveillance and prophylactic cranial irradiation (PCI) to see how well they work compared to MRI surveillance alone in treating patients with small cell lung cancer. MRI scans are used to monitor the possible spread of the cancer with an MRI machine over time. PCI is radiation therapy that is delivered to the brain in hopes of preventing spread of cancer into the brain. The use of brain MRI alone may reduce side effects of receiving PCI and prolong patients' lifespan. Monitoring with MRI scans alone (delaying radiation until the actual spread of the cancer) may be at least as good as the combination of PCI with MRI scans.

British Columbia
BCCA-Vancouver Island Cancer Centre, Victoria
Contact: Site Public Contact    604-877-6010     
Principal Investigator: Julianna Caon        
CancerCare Manitoba, Winnipeg
Contact: Site Public Contact    866-561-1026    [email protected]  
Principal Investigator: Bashir M. Bashir
New Brunswick
Atlantic Health Sciences Corporation-Saint John Regional Hospital, Saint John
Contact: Site Public Contact    506-648-6890     
Principal Investigator: Farah Naz        
Newfoundland and Labrador
Doctor H. Bliss Murphy Cancer Centre, St. John's
Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton
Contact: Site Public Contact    905-387-9495     
Principal Investigator: Anand Swaminath        

Lakeridge Health Oshawa, Oshawa
Contact: Site Public Contact    905-576-8711 ext 4258     
Principal Investigator: Joel Broomfield        

Odette Cancer Centre- Sunnybrook Health Sciences Centre, Toronto
Contact: Site Public Contact    416-480-5000     
Principal Investigator: Alexander V. Louie        

University Health Network-Princess Margaret Hospital, Toronto
Contact: Site Public Contact    416-946-4501    [email protected]  
Principal Investigator: Alexander Y. Sun        
The Research Institute of the McGill University Health Centre (MUHC), Montreal
Contact: Site Public Contact    514-934-1934 ext 48354    [email protected]  
Principal Investigator: Bassam S. Abdulkarim        

CHU de Quebec-L'Hotel-Dieu de Quebec (HDQ), Quebec City
Contact: Site Public Contact       [email protected]  
Principal Investigator: Caroline Lavoie        

Centre Hospitalier Regional de Trois-Rivieres, Trois-Rivieres
Contact: Site Public Contact    819-697-3333 ext 64399     
Principal Investigator: Francois Vincent        
Allan Blair Cancer Centre, Regina
Contact: Site Public Contact    306-766-2213     
Principal Investigator: Nelson Leong         

Talazoparib and Thoracic RT for ES-SCLC Identifier:             NCT04170946     
This study is currently recruiting participants.
This is a phase I, dose escalating study evaluating the safety of combining talazoparib and low dose consolidative thoracic radiotherapy for small cell lung cancer patients. This study will also determine the maximum tolerated dose (MTD) of talazoparib in combination with low dose thoracic radiotherapy.
Patients will start on talazoparib on day 1 of study intervention, and will continue to orally take talazoparib until the last day of radiation therapy. Up to 24 patients will be enrolled to the study, where the first 3 patients will start with a starting dose level of talazoparib is 0.5 mg PO once daily. This will increase to 1mg daily with each new cohort.
Princess Margaret Cancer Center, Toronto
Contact: Benjamin Lok, MD    416-946-4501 ext 5819    [email protected]  

To Assess the Effectiveness and Safety of Zepzelca in Adult Patients With Extensive Stage Small Cell Lung Cancer (SCLC) (SCLC) Identifier:             NCT04894591     
This study is currently recruiting participants.
To assess the effectiveness and safety of Zepzelca in adult participants with extensive stage small cell lung cancer (SCLC) in real-world clinical practice.
New Brunswick
Horizon Health Network, The Moncton Hospital, Moncton
Nova Scotia
Cape Breton Cancer Centre, Sydney
Southlake Regional Health Centre, Newmarket
The Ottawa Hospital Cancer Centre, Ottawa
Princess Margaret Cancer Centre, Toronto
CIUSSS du Saguenay-Lac-Saint-Jean, Chicoutimi
Centre integre de sante et de services sociaux de Chaudiere-Appalaches Levis, Lévis
Integrated Health and Social Services Center of the Lower St. Lawrence (CISSS BSL), Rimouski
CIUSSS de l'Estrie – CHUS, Sherbrooke
Quebec Heart and Lung Institute (IUCPQ-UL), Québec

 A Phase 2 Study of Tarlatamab in Patients With Small Cell Lung Cancer (SCLC) (DeLLphi-301) Identifier:             NCT05060016     
This study is active, but not recruiting participants.
The main aim of this study is to: 
  • evaluate safety and efficacy (per Response Evaluation Criteria in Solid Tumors version 1.1 [RECIST 1.1] by investigator) of 2 dose levels of tarlatamab for Part 1 only
  • evaluate anti-tumor activity of tarlatamab as determined by objective response rate (ORR) per RECIST 1.1 by blinded independent central review (BICR) for Part 1 and 2
  • evaluate safety of reduced mandatory monitoring period in Cycle 1 at selected dose of tarlatamab for Part 3
Princess Margaret Cancer Centre, Toronto